Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.63 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | THRB | P10828 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 3/20 | 0.50 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.47 |
| ▸ | PRKCA | P17252 | 1/20 | 0.47 |
| ▸ | AKT1 | P31749 | 1/20 | 0.47 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 2/20 | 0.47 |
| ▸ | CA1 | P00915 | 2/20 | 0.47 |
| ▸ | CA4 | P22748 | 2/20 | 0.47 |
| ▸ | CA5A | P35218 | 2/20 | 0.47 |
| ▸ | CA7 | P43166 | 2/20 | 0.47 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17509207 | 1.00 | LMNA (0.63) | LMNATSHRCYP2D6ALDH1A1MAPK1 | |
| SCHEMBL17509206 | 1.00 | LMNA (0.63) | LMNATSHRCYP2D6ALDH1A1MAPK1 | |
| SCHEMBL17502024 | 1.00 | LMNA (0.63) | LMNATSHRCYP2D6ALDH1A1MAPK1 | |
| SCHEMBL17502040 | 1.00 | LMNA (0.63) | LMNATSHRCYP2D6ALDH1A1MAPK1 | |
| SCHEMBL971366 | 1.00 | LMNA (0.63) | LMNATSHRCYP2D6ALDH1A1MAPK1 | |
| SCHEMBL24086068 | 1.00 | LMNA (0.63) | LMNATSHRCYP2D6ALDH1A1MAPK1 | |
| SCHEMBL8221876 | 1.00 | LMNA (0.63) | LMNATSHRCYP2D6ALDH1A1MAPK1 | |
| SCHEMBL7572133 | 1.00 | LMNA (0.63) | LMNATSHRCYP2D6ALDH1A1MAPK1 | |
| SCHEMBL17501989 | 0.95 | LMNA (0.60) | LMNATSHRCYP2D6ALDH1A1MAPK1 | |
| SCHEMBL19976407 | 0.95 | LMNA (0.63) | LMNATSHRCYP2D6ALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9149489-B2 | Inhibitors of glycolysis useful in the treatment of brain tumors | BOARD OF REGENTS, UNIVERSITY OF TEXAS SYSTEM (US) | 2015-10-06 | — | — | US | disclosed |
| US-20110003758-A1 | Inhibitors of Glycolysis Useful In the Treatment of Brain Tumors | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-01-06 | — | — | US | disclosed |
| WO-2009108926-A1 | INHIBITORS OF GLYCOLYSIS USEFUL IN THE TREATMENT OF BRAIN TUMORS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2009-09-03 | — | — | WO | disclosed |
| EP-0830365-B1 | MODIFIED KOJIBIOSIDES ANALOGUES | ALBERTA RES COUNCIL (CA) | 2002-09-04 | — | — | EP | disclosed |
| EP-0837867-B1 | MODIFIED ALPHA-D-Glcp-(1-2)-ALPHA-D-Glcp-(1-3)-ALPHA-D-Glcp-ANALOGUES | ALBERTA RES COUNCIL (CA) | 2001-08-16 | — | — | EP | disclosed |
| US-5929037-A | GLUCOSIDASE I INHIBITORS | ALBERTA RESEARCH COUNCIL (CA) | 1999-07-27 | — | — | US | disclosed |
| US-5877157-A | Modified kojibioside analogues | ALBERTA RESEARCH COUNCIL (CA) | 1999-03-02 | — | — | US | disclosed |
| EP-0837867-A1 | MODIFIED $g(a)-D-Glcp-(1-2)-$g(a)-D-Glcp-(1-3)-$g(a)-D-Glcp-ANALOGUES | ALBERTA RESEARCH COUNCIL (CA) | 1998-04-29 | — | — | EP | disclosed |
| EP-0830365-A1 | MODIFIED KOJIBIOSIDES ANALOGUES | ALBERTA RESEARCH COUNCIL (CA) | 1998-03-25 | — | — | EP | disclosed |
| US-5633233-A | Modified kojibiosides analogues | ALBERTA RESEARCH COUNCIL (CA) | 1997-05-27 | — | — | US | disclosed |
| WO-1996040702-A1 | MODIFIED KOJIBIOSIDES ANALOGUES | ALBERTA RESEARCH COUNCIL (CA) | 1996-12-19 | — | — | WO | disclosed |
| WO-1996040700-A1 | MODIFIED α-D-Glcp-(1-2)-α-D-Glcp-(1-3)-α-D-Glcp-ANALOGUES | ALBERTA RESEARCH COUNCIL (CA) | 1996-12-19 | — | — | WO | disclosed |
| US-5075433-A | Substituted-3-sulfatoglucuronic acid antigens | EASTMAN KODAK COMPANY (US) | 1991-12-24 | — | — | US | disclosed |
| EP-0416396-A2 | Tetrasaccharides and process for their preparation | MERCK PATENT GmbH (DE) | 1991-03-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003758-A1 | Inhibitors of Glycolysis Useful In the Treatment of Brain Tumors | PDK2, G6PD, PCK2 | LMNA 3850/4885TSHR 3744/4885CYP2D6 1380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.